title: Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome.
abstract: OBJECTIVE
  To explore the value of serum vascular endothelial growth factor (VEGF) concentrations during IVF cycles in predicting the risk of ovarian hyperstimulation syndrome (OHSS).
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  London Women's Clinic.
  
  
  METHODS
  One hundred seven women undergoing IVF. Mild OHSS developed in 10 women, moderate OHSS in 7, and severe OHSS in 3.
  
  
  METHODS
  Serum VEGF concentrations were measured before treatment, after pituitary desensitization, and on the days of hCG administration, oocyte collection, and ET.
  
  
  METHODS
  Serum VEGF concentrations.
  
  
  RESULTS
  Serum VEGF concentrations were higher in women in whom OHSS developed. The increase in the VEGF concentration that occurred between the day of hCG administration and the day of oocyte collection (the "VEGF rise") was an important marker of OHSS. The VEGF rise was higher in women in whom OHSS developed. A higher VEGF rise predicted all cases of OHSS and moderate/severe cases of OHSS with a sensitivity of 100% and a specificity of 60%. A likelihood ratio test showed that adding the VEGF rise or the VEGF concentration on the day of oocyte collection to a regression model as a continuous variable to the number of follicles, the E2 concentration, and the presence of polycystic ovaries significantly contributed to predicting the risk of OHSS.
  
  
  CONCLUSIONS
  The results support the role of VEGF as an important nonsteroidal index of ovarian response. The VEGF rise may have an advantage over the E2 concentration, the number of follicles, and the number of oocytes, which individually predict only 15%-25% of cases of OHSS.
authors.affiliation: Department of Reproductive Endocrinology, University College London Medical School, The Middlesex Hospital and London Women's Clinic, United Kingdom. ganapaty@dircon.co.uk
authors.forename: R
authors.initials: R
authors.lastname: Agrawal
authors.forename: S L
authors.initials: SL
authors.lastname: Tan
authors.forename: S
authors.initials: S
authors.lastname: Wild
authors.forename: P
authors.initials: P
authors.lastname: Sladkevicius
authors.forename: L
authors.initials: L
authors.lastname: Engmann
authors.forename: N
authors.initials: N
authors.lastname: Payne
authors.forename: J
authors.initials: J
authors.lastname: Bekir
authors.forename: S
authors.initials: S
authors.lastname: Campbell
authors.forename: G
authors.initials: G
authors.lastname: Conway
authors.forename: H
authors.initials: H
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D016228:Endothelial Growth Factors / Q000097:blood*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008222:Lymphokines / Q000097:blood*; D008875:Middle Aged; D006080:Ovarian Follicle / Q000473:pathology; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors